Axogen Free Cash Flow Per Share Growth & History (AXGN)
Axogen's free cash flow per share was -$0.06 for fiscal 2025.
View full Axogen company overviewAxogen annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.06 | -$0.10 | — |
| 2024 | 2024-12-31 | $0.03 | $0.49 | — |
| 2023 | 2023-12-31 | -$0.46 | $0.40 | — |
| 2022 | 2022-12-31 | -$0.86 | $0.14 | — |
| 2021 | 2021-12-31 | -$1.00 | -$0.21 | — |
| 2020 | 2020-12-31 | -$0.79 | -$0.16 | — |
| 2019 | 2019-12-31 | -$0.63 | $0.02 | — |
| 2018 | 2018-12-31 | -$0.65 | -$0.34 | — |
| 2017 | 2017-12-31 | -$0.31 | $0.09 | — |
| 2016 | 2016-12-31 | -$0.40 | $0.12 | — |
| 2015 | 2015-12-31 | -$0.52 | $0.10 | — |
| 2014 | 2014-12-31 | -$0.62 | $0.17 | — |
| 2013 | 2013-12-31 | -$0.79 | -$0.00 | — |
| 2012 | 2012-12-31 | -$0.79 | — | — |
Axogen quarterly free cash flow per share
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.12 | -$0.03 | −22.02% |
| Q1 2026 | 2026-03-31 | -$0.02 | $0.27 | — |
| Q4 2025 | 2025-12-31 | $0.04 | — | — |
| Q3 2025 | 2025-09-30 | $0.04 | -$0.04 | −51.35% |
| Q2 2025 | 2025-06-30 | $0.15 | $0.08 | +104.32% |
| Q1 2025 | 2025-03-31 | -$0.30 | $0.01 | — |
| Q3 2024 | 2024-09-30 | $0.08 | $0.12 | — |
| Q2 2024 | 2024-06-30 | $0.07 | $0.17 | — |
| Q1 2024 | 2024-03-31 | -$0.31 | -$0.03 | — |
| Q3 2023 | 2023-09-30 | -$0.05 | $0.07 | — |
| Q2 2023 | 2023-06-30 | -$0.10 | $0.14 | — |
| Q1 2023 | 2023-03-31 | -$0.28 | $0.11 | — |
| Q3 2022 | 2022-09-30 | -$0.12 | $0.12 | — |
| Q2 2022 | 2022-06-30 | -$0.23 | -$0.02 | — |
| Q1 2022 | 2022-03-31 | -$0.38 | -$0.04 | — |
| Q3 2021 | 2021-09-30 | -$0.24 | -$0.17 | — |
| Q2 2021 | 2021-06-30 | -$0.21 | $0.17 | — |
| Q1 2021 | 2021-03-31 | -$0.34 | -$0.01 | — |
| Q3 2020 | 2020-09-30 | -$0.08 | $0.02 | — |
| Q2 2020 | 2020-06-30 | -$0.38 | -$0.20 | — |
| Q1 2020 | 2020-03-31 | -$0.33 | -$0.09 | — |
| Q3 2019 | 2019-09-30 | -$0.10 | $0.12 | — |
| Q2 2019 | 2019-06-30 | -$0.18 | -$0.06 | — |
| Q1 2019 | 2019-03-31 | -$0.24 | -$0.06 | — |
| Q3 2018 | 2018-09-30 | -$0.22 | -$0.14 | — |
| Q2 2018 | 2018-06-30 | -$0.12 | -$0.05 | — |
| Q1 2018 | 2018-03-31 | -$0.18 | -$0.06 | — |
| Q3 2017 | 2017-09-30 | -$0.07 | $0.01 | — |
| Q2 2017 | 2017-06-30 | -$0.07 | $0.02 | — |
| Q1 2017 | 2017-03-31 | -$0.12 | $0.04 | — |
| Q3 2016 | 2016-09-30 | -$0.08 | $0.03 | — |
| Q2 2016 | 2016-06-30 | -$0.09 | $0.05 | — |
| Q1 2016 | 2016-03-31 | -$0.17 | -$0.06 | — |
| Q3 2015 | 2015-09-30 | -$0.11 | $0.02 | — |
| Q2 2015 | 2015-06-30 | -$0.15 | $0.01 | — |
| Q1 2015 | 2015-03-31 | -$0.11 | $0.08 | — |
| Q3 2014 | 2014-09-30 | -$0.14 | $0.07 | — |
| Q2 2014 | 2014-06-30 | -$0.15 | $0.08 | — |
| Q1 2014 | 2014-03-31 | -$0.19 | $0.05 | — |
| Q3 2013 | 2013-09-30 | -$0.20 | — | — |
| Q2 2013 | 2013-06-30 | -$0.23 | — | — |
| Q1 2013 | 2013-03-31 | -$0.24 | — | — |
| Q2 2011 | 2011-06-30 | -$0.31 | — | — |
Axogen free cash flow per share trends
Over the last five fiscal years, Axogen's free cash flow per share increased from -$0.79 to -$0.06, a change of $0.73. The latest reported quarter, Q2 2026, shows $0.12.
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Axogen source filings ↗Community posts
Axogen pairs a $200 million BioCircuit acquisition with a share offering
Axogen ($AXGN) agreed to acquire BioCircuit Technologies for $200 million in cash, adding the NerveTape platform for sutureless peripheral-nerve repair. The buyer expects the transaction to support revenue growth and improve adjusted EBITDA ...